Lv5
1240 积分 2022-06-07 加入
The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospects
22小时前
已完结
Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery
1天前
已完结
What influences the activity of Degrader−Antibody conjugates (DACs)
2个月前
已完结
Biomacromolecule-mediated targeted protein degradation: an emerging strategy for cancer therapy
2个月前
已完结
Discovery of Novel Potent Triple IKZF1/2/3 Degraders for the Treatment of Hematological Cancers
2个月前
已完结
SJPYT-195: A Designed Nuclear Receptor Degrader That Functions as a Molecular Glue Degrader of GSPT1
2个月前
已完结
Design and Discovery of Preclinical Candidate LYG-409 as a Highly Potent and Selective GSPT1 Molecular Glue Degraders
2个月前
已完结
SOHO State of the Art Updates and Next Questions Acute Myeloid Leukemia: Current Status and Next Questions
3个月前
已完结
T STEM -like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models
3个月前
已完结
Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression
3个月前
已完结
皖公网安备34019202002308
